Australia’s active vaccine safety system

AusVaxSafety has been conducting active safety surveillance of Beyfortus (nirsevimab) – a new long-acting injectable monoclonal antibody product used for the prevention of severe respiratory syncytial virus (RSV) disease in infants – at participating sites in New South Wales and Queensland throughout the 2024 winter season.

In Australia, nirsevimab is currently only available to infants and young children through state-managed programs in New South Wales, Queensland and Western Australia.

Safety data are gathered via surveys sent to recipients in the days following nirsevimab administration.

The Western Australia RSV immunisation program also includes active safety surveillance, with reports published through Government of Western Australia Department of Health channels.

Surveillance of nirsevimab is underway.  This page will be updated once enough data to enable meaningful analysis is collected by AusVaxSafety.